中国产 blaKPC-33 携带型肺炎克雷伯菌 11 型分离株中头孢他啶-阿维巴坦耐药性的出现和恢复。
Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China.
机构信息
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
出版信息
Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S436-S439. doi: 10.1093/cid/ciaa1521.
This is the first report of ceftazidime-avibactam resistance caused by the blaKPC-33 mutation through the D179Y variant during the treatment of blaKPC-2-positive Klebsiella pneumoniae-related infections in China. The blaKPC-33-containing K. pneumoniae was susceptible to meropenem-vaborbactam, cefepime-zidebactam, tigecycline, and polymyxin B. The blaKPC-33 gene was located on a 77 551-bp transformable plasmid harboring qnrS1 and blaLAP-2. Detecting blaKPC-33-positive K. pneumoniae clinical strains is important for infection control.
这是中国首例 blaKPC-33 突变通过 D179Y 变体导致头孢他啶-阿维巴坦耐药的报告，该突变发生在 blaKPC-2 阳性肺炎克雷伯菌相关感染治疗期间。携带 blaKPC-33 的肺炎克雷伯菌对美罗培南-法硼巴坦、头孢吡肟-他唑巴坦、替加环素和黏菌素 B 敏感。blaKPC-33 基因位于一个可转化的 77551bp 质粒上，该质粒携带 qnrS1 和 blaLAP-2。检测 blaKPC-33 阳性肺炎克雷伯菌临床株对感染控制很重要。
Zotero 插件